Having trouble accessing articles? Reset your cache.
FDA ordered Abbott Laboratories (NYSE:ABT) to withdraw obesity drug Meridia sibutramine in the U.S. The agency said Meridia's availability is not justified when comparing the "very modest weight loss"
Get a two-week free trial subscription to BioCentury